Conexeu Sciences Inc. reported significant expansion in consulting, management, and regulatory activities in the quarter ending April 30, 2026, fueling a sharp rise in operating losses to over $2.3 million for the quarter. The company executed a direct listing on Nasdaq in May 2026, marking a key milestone in its pre-commercialization journey. With $6.8 million in cash, Conexeu is advancing its biomaterial platform development and preparing for a planned 510(k) FDA submission while ramping investor relations efforts. Substantial doubt about its ability to continue as a going concern persists without additional financing.